Jefferies Calls Bottom on Gene Therapy Stock After Huge Sell-Off

AXGT has sold off massively in the past 12 months

Jun 12, 2019 at 10:30 AM
facebook twitter linkedin


Axovant Sciences Ltd (NASDAQ:AXGT) has seen its stock fall from the mid-$30 range to yesterday's close of $3.94, even after positive data for its Parkinson's treatment. However, Jefferies referred to the shares as "remarkably cheap" and even though it cut its price target to $16 from $24, it kept its "buy" rating in place, obviously expecting huge upside for the gene therapy specialist.

This follows the company's earnings release last night, where it reported a loss of 45 cents, compared to expectations for a larger loss of $1.70. Despite this, the shares are trading lower again today, down 1% at $3.90.

Some options traders have been speculating on an upside move, with the June 6 and 7 calls seeing heavy trading in the past 10 days. In Tuesday's trading, the July 4 call was popular. Overall, 349 calls were bought to open during the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), compared to 26 puts.

Meanwhile, short interest fell by 88% in the last two reporting periods, but 10% of the float remains dedicated to short interest. Going by average daily trading volumes, this accounts for 3.2 days' worth of buying power.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners